Tislelizumab-jsgr approved with chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma, showing significant survival benefits. RATIONALE-305 study demonstrated a 20% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results